ATAI - ATAI Life Sciences N.V.
IEX Last Trade
1.275
-0.010 -0.784%
Share volume: 14,623
Last Updated: Fri 27 Dec 2024 08:30:07 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$1.28
-0.01
-0.78%
Fundamental analysis
30%
Profitability
25%
Dept financing
5%
Liquidity
75%
Performance
30%
Performance
5 Days
4.17%
1 Month
-27.75%
3 Months
6.84%
6 Months
-5.30%
1 Year
-19.35%
2 Year
-47.70%
Key data
Stock price
$1.28
DAY RANGE
$1.24 - $1.34
52 WEEK RANGE
$1.10 - $2.85
52 WEEK CHANGE
-$11.35
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Florian Brand
Region: US
Website: atai.life
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: atai.life
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Atai Life Sciences N.V. operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD)
Recent news